NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded Hologic's stock from Outperform to Market Perform and lowered its price target on the shares.
The bank cited growth headwinds for Hologic's NovaSure, ThinPrep, and legacy 2D mammography sales, as well as Gen-Probe pricing pressures. It said that, overall, the positives for the firm are not occurring quickly enough to offset these headwinds.